See the latest news and media coverage for Pfizer. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company
pfizer.comLast updated
In short: Pfizer expanded its oncology and rare disease portfolios while managing leadership changes and navigating multi-national patent litigation.
The partnership aims to accelerate R&D of 12 early-stage oncology programs, including ADCs and multi-specific antibodies, combining Pfizer's global expertise with Innovent's discovery capabilities.
The company emphasizes its commitment to patients and delivering breakthroughs that change lives.
The study involves a potential first-in-class IL4/13 and TSLP trispecific antibody for atopic dermatitis. It supports advancing a broad program for Type 2 inflammatory conditions.
The company delivered patient-changing breakthroughs and anticipates 2026 with focus and commitment.
OPINION Posted: PFIZER INC. v. SANOFI VACCINES US INC. [OPINION](pdf) Appeal Number: 24-2199 Origin: PTO Nonprecedential To see more opinions and orders, follow this link...
Pfizer’s Litfulo is already approved in alopecia areata; however, the success of the TRANQUILLO prog...
On July 30, 2026, Pfizer Inc. (PFE) announced that its oral hair loss medication, Litfulo, has...
Pfizer (PFE) says hair loss therapy Litfulo succeeded in two Phase 3 trials for nonsegmental...
Track Pfizer and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Pfizer and other trending companies.